Similar results have been reported from a study by Malhotra et al.: MS patients who responded well to IFNβ showed lower mRNA levels of NLRP3 and IL-1β as compared to their pretreatment levels; conversely, nonresponders experienced upregulation of NLRP3 and IL-1β mRNA levels after three months of treatment with IFNβ [90]. Here, IFNB1 is linked to myeloid sarcoma.